Annual report pursuant to Section 13 and 15(d)

Significant Transactions (Tables)

v3.23.1
Significant Transactions (Tables)
 12 Months Ended
Dec. 31, 2022
Viridian Sciences Inc. [Member]  
Business Acquisition [Line Items]  
Schedule of estimated acquisition date fair value of consideration

Shares issued

 

$

6,186

 

Contingent consideration

2
Total fair value of consideration transferred
$ 6,188
Schedule of preliminary estimated fair values of assets acquired and liabilities

Accounts receivable

 

$

556

 

Prepaid expenses and other current assets

 

 

148

 

Capitalized software

423

Acquired technology

 

 

470

 

Customer relationships

820
Acquired trade name

20
Goodwill

5,408

Accounts payable and accrued expenses

 

 

(350

 )
Deferred tax liabilities

(307 )

Deferred revenue

 

 

(1,000

 )

Net assets acquired

 

$

6,188

 

365 Cannabis [Member]  
Business Acquisition [Line Items]  
Schedule of estimated acquisition date fair value of consideration

Shares issued

 

$

11,060

 

Cash

4,982
Contingent consideration

6,300
Total fair value of consideration transferred
$ 22,342
Schedule of preliminary estimated fair values of assets acquired and liabilities
Cash

527
Accounts receivable

 

 

486

 

Prepaid expenses and other current asset

261
Fixed Assets

93
Non-compete agreement

80

Acquired technology

 

 

1,040

 

Customer relationships

13,810
Acquired trade name

270
Goodwill

12,489

Accounts payable and accrued expenses

 

 

(2,588

 )
Deferred tax liabilities

(826 )

Deferred revenue

 

 

(3,300

 )

Net assets acquired

 

$

22,342